证券日报网讯 12月2日，爱朋医疗在互动平台回答投资者提问时表示，公司布局了非侵入式脑机接口产 品ADHD行为治疗管理系统和顽固性失眠麻醉治疗系统。ADHD行为治疗和顽固性失眠治疗在院内均有 相应的收费目录。同时湖北、浙江、江苏等地相继出台脑机接口相关医疗服务价格项目，相关政策也将 推进脑机接口临床实践及应用提速。 （文章来源：证券日报） ...

Core Viewpoint - Aipeng Medical (300753) is actively engaging with favorable policies for the brain-computer interface industry, aiming to leverage these opportunities for business growth [1] Group 1: Policy Support - The Minhang District has tailored specific policies to support the brain-computer interface industry, focusing on three main areas of robust support [1] - Key financial incentives include subsidies for leading companies up to 20 million yuan, annual R&D funding of up to 2 million yuan for three consecutive years, and awards for competition-winning projects up to 2 million yuan [1] - Significant platform construction can receive subsidies up to 50 million yuan, along with rent reductions of 100%, 50%, and 25% [1] Group 2: Company Response - Aipeng Medical acknowledges the importance of national and regional policies related to brain-computer interfaces and is committed to seizing these policy opportunities to enhance its business development [1]

格隆汇12月2日丨爱朋医疗(300753.SZ)在投资者互动平台表示，公司布局了非侵入式脑机接口产品 ADHD行为治疗管理系统和顽固性失眠麻醉治疗系统。ADHD行为治疗和顽固性失眠治疗在院内均有相 应的收费目录。同时湖北、浙江、江苏等地相继出台脑机接口相关医疗服务价格项目，相关政策也将推 进脑机接口临床实践及应用提速。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司与东部战区总医院有业务往来吗？ 爱朋医疗（300753.SZ）12月2日在投资者互动平台表示，公司与东部战区总医院在疼痛管理微电脑注药 泵系列产品上已产生业务合作，业绩占比较小。在脑机接口领域暂未与其合作。敬请广大投资者理性决 策，谨慎投资，注意投资风险。 ...

Core Insights - The brain-computer interface (BCI) industry in China is expected to enter a significant development phase by 2025, driven by strong policy support and capital investment [1][5][6] - The BCI sector has seen substantial investment activity, with 28 financing rounds completed in 2023, totaling over 5 billion yuan [1] - The A-share market has recognized BCI as a hot investment trend, with the BCI concept index rising by 52.13% over the past year, significantly outperforming the Shanghai and Shenzhen 300 index [1] Policy Support - The "14th Five-Year Plan" emphasizes BCI as one of the six key future industries, with a clear timeline for technological breakthroughs and industry development by 2027 and 2030 [5][6] - In July, a joint initiative from seven departments outlined strategies for BCI innovation and development, aiming to establish a robust industry ecosystem [5] - Shanghai has proactively developed a BCI action plan, targeting clinical applications and technological advancements by 2027 and 2030 [6] Market Performance - The BCI concept index (8841700.WI) has shown a remarkable increase, with notable stocks like Innovation Medical and Hanwei Technology experiencing gains of 170% and 139.48% respectively [2][1] - A total of 24 A-share companies are involved in the BCI sector, with an average revenue of 3.43 billion yuan and an average net profit of 431 million yuan for the first three quarters of the year [11] Industry Landscape - The BCI industry in China is rapidly evolving, with over 800 core enterprises identified, positioning China among the leading countries in this field [8] - Recent clinical trials, including the first invasive clinical trial in China, indicate significant advancements in BCI technology [8][9] - The launch of the "North Brain No. 1" GCP multi-center clinical trial marks a new phase in large-scale clinical validation of BCI systems [9] Company Developments - Companies like Lepu Medical and Aipeng Medical are actively pursuing commercialization of BCI products, with Lepu focusing on deep brain stimulation devices and Aipeng on EEG collection products [12][13] - Aipeng Medical has established a joint laboratory for ADHD treatment, indicating a focus on integrating BCI technology into clinical applications [13] - Recent regulatory changes, including the establishment of a "green channel" for insurance coding of innovative medical products, are expected to accelerate the clinical application of BCI technologies [13]

证券日报网讯爱朋医疗（300753）11月26日在互动平台回答投资者提问时表示，公司内部构建了系统性 战略导向型人才培养和激励体系，未来公司将根据经营情况，积极研究并适时开展股权激励等措施。 ...

格隆汇11月26日丨爱朋医疗(300753.SZ)在互动平台表示，公司暂无创新药相关研发或代销。 ...

Core Viewpoint - Aipeng Medical (300753) is actively exploring new equity incentive mechanisms in response to the growing focus on brain-computer interface technology and its own strategic initiatives in this area [1] Group 1: Company Initiatives - Aipeng Medical has previously implemented a three-year restricted stock incentive plan, which concluded in 2021 [1] - The company is currently accelerating its efforts in the brain-computer interface innovation business [1] Group 2: Future Plans - Aipeng Medical is developing a systematic strategic talent cultivation and incentive system [1] - The company plans to research and potentially implement new equity incentive measures based on its operational conditions in the future [1]

分红方面，爱朋医疗A股上市后累计派现1.13亿元。近三年，累计派现1638.62万元。 爱朋医疗今年以来股价涨51.84%，近5个交易日跌13.16%，近20日跌11.04%，近60日跌24.70%。 11月19日，爱朋医疗盘中下跌2.09%，截至11:29，报26.67元/股，成交5657.84万元，换手率2.39%，总 市值33.62亿元。 爱朋医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：机器人概念、人工智 能、人脑工程（脑机接口）、专精特新、医用耗材等。 资金流向方面，主力资金净流出639.98万元，大单买入643.01万元，占比11.36%，卖出1282.99万元，占 比22.68%。 截至9月30日，爱朋医疗股东户数2.21万，较上期减少31.76%；人均流通股3972股，较上期增加 46.51%。2025年1月-9月，爱朋医疗实现营业收入2.52亿元，同比减少8.41%；归母净利润-1148.42万 元，同比减少401.64%。 今年以来爱朋医疗已经6次登上龙虎榜，最近一次登上龙虎榜为8月8日，当日龙虎榜净买入1192.43万 元；买入总计7835.89万元 ，占总成交额比 ...

Core Insights - Aipeng Medical (300753.SZ) has multiple products in the brain-computer interface (BCI) field that have been commercialized, including an anesthetic depth monitor for perioperative brain state monitoring and a treatment system for refractory insomnia [1] - The company has a stake in Changzhou Ruishen'an Medical, which has received approval for its implanted deep brain stimulation device [1] - Currently, the company does not have any products applying for the special review process for innovative medical devices [1] Industry Developments - The first invasive brain-computer interface product, a "wireless implanted brain-computer interface system" developed by Shanghai Ladder Medical Technology Co., has entered the special review process of the National Medical Products Administration (NMPA), marking a significant step in the industrialization of this cutting-edge technology in China [3] - This development indicates a shift from clinical validation to market access for BCI products in China, highlighting the growing importance of this technology in the medical field [3]